CA2477675C - Immunizing composition and method for inducing an immune response against the .beta.-secretase cleavage site of amyloid precursor protein - Google Patents

Immunizing composition and method for inducing an immune response against the .beta.-secretase cleavage site of amyloid precursor protein Download PDF

Info

Publication number
CA2477675C
CA2477675C CA2477675A CA2477675A CA2477675C CA 2477675 C CA2477675 C CA 2477675C CA 2477675 A CA2477675 A CA 2477675A CA 2477675 A CA2477675 A CA 2477675A CA 2477675 C CA2477675 C CA 2477675C
Authority
CA
Canada
Prior art keywords
beta
seq
antigenic peptide
immunizing composition
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2477675A
Other languages
English (en)
French (fr)
Other versions
CA2477675A1 (en
Inventor
Beka Solomon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Publication of CA2477675A1 publication Critical patent/CA2477675A1/en
Application granted granted Critical
Publication of CA2477675C publication Critical patent/CA2477675C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA2477675A 2002-03-05 2003-03-04 Immunizing composition and method for inducing an immune response against the .beta.-secretase cleavage site of amyloid precursor protein Expired - Fee Related CA2477675C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36134402P 2002-03-05 2002-03-05
US60/361,344 2002-03-05
PCT/US2003/006388 WO2003076455A2 (en) 2002-03-05 2003-03-04 Immunizing composition and method for inducing an immune response against the ss-secretase cleavage site of amyloid precursor protein

Publications (2)

Publication Number Publication Date
CA2477675A1 CA2477675A1 (en) 2003-09-18
CA2477675C true CA2477675C (en) 2013-05-21

Family

ID=27805031

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2477675A Expired - Fee Related CA2477675C (en) 2002-03-05 2003-03-04 Immunizing composition and method for inducing an immune response against the .beta.-secretase cleavage site of amyloid precursor protein

Country Status (8)

Country Link
US (3) US7494655B2 (enExample)
EP (2) EP2292247A3 (enExample)
JP (3) JP2005532276A (enExample)
AU (1) AU2003225636A1 (enExample)
CA (1) CA2477675C (enExample)
ES (1) ES2392247T3 (enExample)
IL (3) IL163812A0 (enExample)
WO (1) WO2003076455A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1398019A1 (de) 2002-09-13 2004-03-17 Cognis France S.A. Verfahren zum Schutz und zur Modulation von Dermal Epidermal Junctions
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2005033278A2 (en) * 2003-09-30 2005-04-14 Ludwig Institute For Cancer Research In vivo efficacy of ny-eso-1 plus iscom
BRPI0516674A (pt) * 2004-10-28 2008-09-16 Sanko Junyaku Kk método de análise de mal de alzheimer e reagente de diagnóstico
JP5213718B2 (ja) 2005-10-18 2013-06-19 スターファーマ・プロプライエタリー・リミテッド 殺微生物性デンドリマー組成物のデリバリーシステム
HUE031341T2 (hu) 2005-10-25 2017-07-28 Starpharma Pty Ltd Ellenõrzött sztöchiometriájú makromolekuláris vegyületek
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
WO2007082331A1 (en) 2006-01-20 2007-07-26 Starpharma Pty Limited Modified macromolecule
AU2007229268B2 (en) 2006-03-22 2013-01-10 Starpharma Pty Limited Contraceptive composition
US20090324554A1 (en) * 2006-07-21 2009-12-31 Ramot At Tel Aviv University Ltd. Method for inhibiting or treating a disease associated with intracellular formation of protein fibrillar or aggregates
WO2008017125A1 (en) 2006-08-11 2008-02-14 Starpharma Pty Ltd Targeted polylysine dendrimer therapeutic agent
EP2091959A4 (en) 2006-11-28 2010-05-05 Alzhyme Pty Ltd IMPROVED PEPTIDE COMPOSITION
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
WO2009041501A1 (ja) 2007-09-27 2009-04-02 Virus Ikagaku Kenkyusho Inc. ヘルペスウイルスの潜伏感染に関与する因子及びその利用
GB0720912D0 (en) 2007-10-25 2007-12-05 Univ Cardiff Monoclonal Anitbody for APP
KR101397554B1 (ko) * 2007-11-09 2014-05-21 재단법인서울대학교산학협력재단 치매(알츠하이머 병)의 진단, 예방, 치료제 및 이들의스크리닝 방법
CA2707859A1 (en) 2007-12-11 2009-06-18 Glaxo Group Limited Antigen binding proteins specific against beta amyloid
WO2009124119A2 (en) * 2008-04-01 2009-10-08 The Trustes of Columbia University in the City of New York Phosphodiesterase inhibitors and uses thereof
WO2009155538A1 (en) * 2008-06-20 2009-12-23 Merck & Co., Inc. Compositions and methods of depleting amyloid-beta peptides from cerebrospinal fluid to treat alzheimer's disease
AR073295A1 (es) 2008-09-16 2010-10-28 Genentech Inc Metodos para tratar la esclerosis multiple progresiva. articulo de fabricacion.
AU2009316326A1 (en) * 2008-11-24 2010-05-27 Ramot At Tel-Aviv University Ltd. Method for treating Parkinson' s disease using filamentous bacteriophage
JP2012513464A (ja) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
WO2011031720A1 (en) * 2009-09-11 2011-03-17 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Bispecific nanobodies as a therapeutic for alzheimer's disease
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
WO2015199247A1 (ja) * 2014-06-27 2015-12-30 日本たばこ産業株式会社 気分障害を診断、治療又は予防する方法
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN106349334A (zh) * 2015-07-15 2017-01-25 韩震 一种多肽化合物及其制备方法与应用
JP6641387B2 (ja) 2015-12-28 2020-02-05 日本たばこ産業株式会社 融合タンパク質及びその利用
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376861A (en) 1976-06-23 1983-03-15 The Dow Chemical Company Method for preparing 2-alkenyl-2-oxazolines
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4517122A (en) 1982-02-12 1985-05-14 The Dow Chemical Company Cyclic peptides
US4600535A (en) 1982-02-12 1986-07-15 The Dow Chemical Company Cyclic peptides
US4558120A (en) 1983-01-07 1985-12-10 The Dow Chemical Company Dense star polymer
US4507466A (en) 1983-01-07 1985-03-26 The Dow Chemical Corporation Dense star polymers having core, core branches, terminal groups
US4568737A (en) 1983-01-07 1986-02-04 The Dow Chemical Company Dense star polymers and dendrimers
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4515920A (en) 1984-04-30 1985-05-07 The Rockefeller University Synthesis of peptides and proteins
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
US4587329A (en) 1984-08-17 1986-05-06 The Dow Chemical Company Dense star polymers having two dimensional molecular diameter
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US4599400A (en) 1984-12-18 1986-07-08 The Dow Chemical Company Star/comb-branched polyamide
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5096815A (en) 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5268164A (en) 1990-04-23 1993-12-07 Alkermes, Inc. Increasing blood-brain barrier permeability with permeabilizer peptides
JPH06507782A (ja) * 1990-06-15 1994-09-08 サイオス　ノバ　インコーポレイテッド アルツハイマー病のアミロイド形成開症状を示すヒト以外の組換え哺乳動物
US5222982A (en) 1991-02-11 1993-06-29 Ommaya Ayub K Spinal fluid driven artificial organ
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5580563A (en) 1992-05-01 1996-12-03 Tam; James P. Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof
US5716614A (en) 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
US5744346A (en) 1995-06-07 1998-04-28 Athena Neurosciences, Inc. β-secretase
JPH11507538A (ja) 1995-06-07 1999-07-06 アテナ ニューロサイエンシズ インコーポレイティド β−セクレターゼ、β−セクレターゼに対する抗体、及びβ−セクレターゼ阻害を検出するためのアッセイ
US6221645B1 (en) 1995-06-07 2001-04-24 Elan Pharmaceuticals, Inc. β-secretase antibody
US5719867A (en) 1995-06-30 1998-02-17 Scientific-Atlanta, Inc. Plural telephony channel baseband signal demodulator for a broadband communications system
WO1998021589A1 (en) 1996-11-15 1998-05-22 The Trustees Of The University Of Pennsylvania Screening for modulators of amyloid processing
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6703015B1 (en) 1999-09-03 2004-03-09 Ramot At Tel-Aviv University Ltd. Filamentous bacteriophage displaying an β-amyloid epitope
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6313268B1 (en) 1998-10-16 2001-11-06 Vivian Y. H. Hook Secretases related to Alzheimer's dementia
WO2000047618A2 (en) 1999-02-10 2000-08-17 Elan Pharmaceuticals, Inc. HUMAN β-SECRETASE ENZYME, INHIBITORS AND THEIR COMPOSITIONS AND USES
WO2001014579A2 (en) * 1999-08-26 2001-03-01 Vion Pharmaceuticals, Inc. Compositions and methods for delivery of an agent using attenuated salmonella containing phage
US20040013647A1 (en) 1999-09-03 2004-01-22 Ramot At Tel-Aviv University Ltd. Methods and compositions for treating a plaque-forming disease
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
JP2003509020A (ja) 1999-09-03 2003-03-11 ラモット・ユニバーシティ・オーソリティ・フォー・アプライド・リサーチ・アンド・インダストリアル・ディベロップメント・リミテッド プラーク形成疾患の診断、治療、予防に有用な薬剤、組成物、その使用法
AU2001229592A1 (en) * 2000-01-21 2001-07-31 University Of Connecticut Health Center Vaccines against neurodegenerative disorders
DE60217107T2 (de) * 2001-06-20 2007-08-23 Ramot At Tel Aviv University Ltd. Mehrantigenisches peptid enthaltend mehrere kopien eines epitopes von einem ablagerungsformenden polypeptid und dessen verwendung
US20070134247A9 (en) 2002-04-12 2007-06-14 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
GB0720912D0 (en) * 2007-10-25 2007-12-05 Univ Cardiff Monoclonal Anitbody for APP

Also Published As

Publication number Publication date
AU2003225636A8 (en) 2003-09-22
US20070172484A1 (en) 2007-07-26
AU2003225636A1 (en) 2003-09-22
IL212752A0 (en) 2011-07-31
WO2003076455A3 (en) 2004-04-08
EP2292247A3 (en) 2011-10-05
JP2010248197A (ja) 2010-11-04
US20110070249A1 (en) 2011-03-24
JP2013181034A (ja) 2013-09-12
US7494655B2 (en) 2009-02-24
IL163812A (en) 2011-06-30
US8613928B2 (en) 2013-12-24
IL212752A (en) 2014-01-30
ES2392247T3 (es) 2012-12-07
EP1480666A4 (en) 2006-06-07
EP2292247A2 (en) 2011-03-09
EP1480666B1 (en) 2012-06-13
US20060034855A1 (en) 2006-02-16
CA2477675A1 (en) 2003-09-18
JP2005532276A (ja) 2005-10-27
US7854931B2 (en) 2010-12-21
JP5717210B2 (ja) 2015-05-13
EP1480666A2 (en) 2004-12-01
IL163812A0 (en) 2005-12-18
WO2003076455A2 (en) 2003-09-18

Similar Documents

Publication Publication Date Title
US7854931B2 (en) Immunizing compostion and method for inducing an immune response against the beta-secretase cleavage site of amyloid precursor protein
US11673944B2 (en) Treatment of tauopathies
AU2009217216B2 (en) Mimotopes of alpha-synuclein and vaccines thereof for the treatment of neurodegenerative disorders
AU2013305848B2 (en) Compositions and methods related to diseases associated with deposits of amyloid, Tau, and alpha-synuclein
JP5901714B2 (ja) アルファシヌクレイン・エピトープのミモトープのレヴィ小体病治療への使用
ZA200505782B (en) Active immunization to generate antibodies to soluble A-beta
AU2005273969A2 (en) Prevention and treatment of synucleinopathic and amyloidogenic disease
EP1397380B1 (en) Multiple antigenic peptide displaying multiple copies of an epitope of a plaque-forming polypeptide and methods of using same
WO2003033644A2 (en) Peptide useful in immunomodulation
US20060276400A1 (en) Modulation of cholesteryl ester transfer protein (CETP) activity
WO2000025814A2 (en) Component for vaccine against serogroup b meningococci

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150304